IR@PKUHSC  > 北京大学第二临床医学院  > 胃肠外科
学科主题临床医学
A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1
Yan, Yichao1; Shen, Zhanlong1; Ye, Yingjiang1; Jiang, Kewei1; Zhang, Hui1; Shen, Chao1; Mustonen, Harri2; Puolakkainen, Pauli2; Wang, Shan1
关键词Vasohibin-1 Colorectal Cancer Invasion Metastasis Prognosis
刊名MEDICAL ONCOLOGY
2014-02-01
DOI10.1007/s12032-013-0816-0
31期:2
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]EPITHELIUM-DERIVED FACTOR ; ANGIOGENESIS INHIBITOR ; ENDOTHELIAL-CELLS ; CHONDROMODULIN-I ; EXPRESSION ; NEOVASCULARIZATION ; MECHANISMS ; CARCINOMA ; DISEASE ; SWITCH
英文摘要

Vasohibin-1 has been recently detected in endothelial cells and identified as a negative feedback regulator of angiogenesis induced by VEGF-A. However, the expression of Vasohibin-1 in colorectal cancer and its correlations with VEGF-A, microvessel density (MVD), and the prognosis of the patients remain unclear. In this study, Vasohibin-1 and VEGF-A expression were measured in 132 paraffin-embedded tissues of colorectal cancer by immunohistochemistry and Western blot, as well as in colon cancer cell lines with different metastatic potential and in normal colon cell by Western blot and real-time PCR. MVD was measured by counting CD34 positive clusters in a single field of view with the most intensive neovascularization of colon cancer tissues. The correlation between the expression of Vasohibin-1, VEGF-A, MVD, clinicopathological features, and prognosis was analyzed. We found that Vasohibin-1 and VEGF-A proteins were expressed in 88.64 % (117/132) and 84.09 % (111/132) colorectal cancer tissues, respectively. Strongly positive correlations were found between Vasohibin-1, VEGF-A expression, and MVD in the colorectal cancer tissues (Vasohibin-1 vs. VEGF-A: r = 0.688, P < 0.001; Vasohibin-1 vs. MVD: r = 0.483, P < 0.001; VEGF-A vs. MVD: r = 0.491, P < 0.001). Vasohibin-1 expression has significant positive correlation with pathological TNM stage (P = 0.001), tumor stromal invasion (P = 0.004), lymph node status (P = 0.003), and distant metastasis (P = 0.033), but no correlation with tumor differentiation (P = 0.756). The patients with high Vasohibin-1 expression had significantly worse overall survival (OS) and progression-free survival (PFS) than those with low Vasohibin-1 expression (OS: P = 0.001; PFS: P = 0.003). In addition, Vasohibin-1 protein expression is an independent risk factor affecting OS and PFS. Therefore, we conclude that Vasohibin-1 is a clinically relevant predictor of patient prognosis in colorectal cancer. Vasohibin-1 might become a new biomarker and provide additional prognostic information in patients with colorectal cancer.

语种英语
WOS记录号WOS:000331977900006
项目编号81372290 ; 81372291 ; 7112136 ; 2107000074 ; RDB 2012-18 ; RDB 2013-15
资助机构National Natural Science Foundation ; Beijing Municipal Natural Science Foundation ; Beijing Science and Technology Project ; Peking University People&prime ; s Hospital Research and Development Funds
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53638
专题北京大学第二临床医学院_胃肠外科
作者单位1.Peking Univ, Peoples Hosp, Dept Surg Gastroenterol, Beijing 100044, Peoples R China
2.Univ Helsinki, Cent Hosp, Dept Surg, FIN-00290 Helsinki, Finland
推荐引用方式
GB/T 7714
Yan, Yichao,Shen, Zhanlong,Ye, Yingjiang,et al. A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1[J]. MEDICAL ONCOLOGY,2014,31(2).
APA Yan, Yichao.,Shen, Zhanlong.,Ye, Yingjiang.,Jiang, Kewei.,Zhang, Hui.,...&Wang, Shan.(2014).A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1.MEDICAL ONCOLOGY,31(2).
MLA Yan, Yichao,et al."A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1".MEDICAL ONCOLOGY 31.2(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yan, Yichao]的文章
[Shen, Zhanlong]的文章
[Ye, Yingjiang]的文章
百度学术
百度学术中相似的文章
[Yan, Yichao]的文章
[Shen, Zhanlong]的文章
[Ye, Yingjiang]的文章
必应学术
必应学术中相似的文章
[Yan, Yichao]的文章
[Shen, Zhanlong]的文章
[Ye, Yingjiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。